Forward Pharma A/S
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Claus Svendsen
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Oestergade 24A, 1, Copenhagen K Koebenhavn K Denmark 1100
- IPO Date
- Oct 15, 2014
- CIK
- 0001604924
- Website
- forward-pharma.com
- Similar Companies
- Business
- Forward Pharma A/S is a pharmaceutical company specializing in the development and commercialization of innovative drugs primarily focused on the treatment of multiple sclerosis and other neurological disorders. The company's core products and services include proprietary pharmaceutical compounds, including its leading product candidate for relapsing multiple sclerosis; research and development of novel drug candidates; and licensing of pharmaceutical technologies. Forward Pharma operates primarily in Europe and North America, conducting clinical trials and regulatory activities in these regions. Founded in 2005, the company is headquartered in Copenhagen, Denmark. In the last 1-2 years, Forward Pharma has undergone significant strategic changes. These include forging new partnerships and strategic alliances to advance its clinical development pipeline, initiating new clinical trials to expand indications for its drug candidates, and enhancing its licensing agreements. The company has also focused on operational efficiency improvements and expanding its market reach through collaborations with global pharmaceutical firms. There have been no recent changes in company name or major reorganizations reported. Forward Pharma serves the pharmaceutical industry with a business focus on research, development, and commercialization of specialty drugs targeting neurological diseases. Its target customers are healthcare providers, pharmaceutical partners, and patients suffering from multiple sclerosis and related conditions. The company operates through direct pharmaceutical development and collaboration models in key markets across Europe and the United States. It maintains its headquarters in Copenhagen and continues to invest in innovation for neurological therapeutics.
Why is Forward Pharma Stock Plunging During Premarket Tuesday?
FWP Stock: Over 20% Decrease Pre-Market Explanation
Forward Pharma Announces the Decision of the Technical Board of Appeal of the European Patent Office in the EP2801355 Appeal Hearing
Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2020
Forward Pharma Announces Rescheduling of the EP2801355 Appeal Hearing to September 6, 2021 due to COVID-19 Restrictions
Goldman Sachs Group Upgrades Chr. Hansen Holding A/S (OTCMKTS:CHYHY) to Neutral
Chr. Hansen Holding A/S (OTCMKTS:CHYHY) Given Consensus Recommendation of “Hold” by Analysts
Denmark stocks higher at close of trade; OMX Copenhagen 20 up 0.65%
Analysts Set Ascendis Pharma A/S (NASDAQ:ASND) Price Target at $176.50
Nuveen Asset Management LLC Has $1.79 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)
$1.94 Million in Sales Expected for Ascendis Pharma A/S (NASDAQ:ASND) This Quarter
Chr. Hansen Holding A/S (OTCMKTS:CHYHY) Given “Neutral” Rating at Credit Suisse Group
Comparing Cal-Maine Foods (NASDAQ:CALM) and JBS S A/S (NASDAQ:JBSAY)
Analyzing JBS S A/S (OTCMKTS:JBSAY) and BIQI International (OTCMKTS:BIQIF)
Ascendis Pharma A/S (NASDAQ:ASND) Cut to Hold at BidaskClub
COVID-19's impact Global Monoclonal Antibodies Market 2020 Segmented by Application and Geography Trends, Growth and Forecasts to 2025
Global Precision Medicine Market 2020-2030: Focus on Ecosystem, Technology, Application, and Competitive Landscape - ResearchAndMarkets.com
Neuberger Berman Group LLC Grows Position in AMBEV S A/S (NYSE:ABEV)
Genmab A/S (NASDAQ:GMAB) Shares Gap Down to $38.20
COVID-19 Recovery Analysis: Crushing Equipment Market | Use Of Artificial Sand For Construction Work to Boost the Market Growth | Technavio